CRISPR Epigenome Editing: Advances in Gene Expression Control and Remaining Challenges for Clinical Translation

Background: A therapeutic strategy for regulating gene expression
CRISPR/Cas-based epigenome editing is advancing toward precise control of when genes are expressed in human cells, at what levels, and for how long. As early technologies enter clinical trials, the key challenges for therapeutic translation are delivery, performance, and safety. A paper published in Current Opinion in Biomedical Engineering in June 2026 reviewed recent advances in the field and the challenges of clinical translation. It differs from a study reporting the clinical efficacy of an individual therapy.
Epigenome editing focuses on regulating gene expression and epigenetic states rather than correcting DNA sequences. The authors highlighted its potential to identify new therapeutic targets and improve gene and cell therapies while reducing the genotoxicity associated with conventional genome editing—that is, the risk of damage to genetic material. The potential to reduce genotoxic risk must be distinguished from evidence establishing the safety of an individual tool.
Potential applications discussed in the paper include diseases involving abnormalities in transcription and epigenetic regulation. These include diseases that are difficult to address with conventional genome editing because of abnormal repeat regions or complex genomic arrangements. This describes problems that an expression-regulation approach might address; it does not report confirmed treatment effects for specific diseases.
Key findings: Controlling expression and miniaturizing editing tools
The advances highlighted in the abstract include an improved ability to precisely control the timing, level, and duration of expression of genes naturally present in human cells, and to reset epigenetic states. New strategies are also being developed to regulate cell fate and function. The authors considered these developments likely to offer new options for cell therapy and regenerative medicine research.
Development approaches to improve delivery include identifying compact Cas proteins and engineering smaller effectors. These efforts aim to deliver editing tools efficiently. However, the available abstract does not report percentage reductions in size or loading performance for individual delivery vehicles, making it difficult to compare the quantitative outcomes of miniaturization.
The ability to distinguish intended targets is another major area of development. Research is under way to develop new effector domains with high specificity and adequate performance while avoiding immunogenicity and cytotoxicity. Immunogenicity means the capacity to trigger an immune response. Progress in efforts to improve these properties does not itself demonstrate an absence of adverse effects in humans.
Implications and outlook: Delivery, performance, and safety require joint evaluation
The paper notes that early CRISPR/Cas-based epigenome-editing technologies have entered clinical trials. However, the provided abstract gives no trial phases, target diseases, patient characteristics, or efficacy and safety results. Entry into clinical trials alone is insufficient to judge therapeutic benefit or when a treatment might become available.
Clinical translation requires evaluating together the ability to deliver tools efficiently, their performance in achieving the intended expression control, and their target selectivity, immunogenicity, and cytotoxicity. Reported advances in controlling expression duration must also be distinguished from proof of long-term therapeutic benefit. This paper provides a basis for examining the direction of technological development and the challenges ahead. Assessing the clinical value of individual candidates requires supporting data from the relevant experiments and clinical trials.
Source: Bibliographic information and abstract for Clinical translation of epigenome editing technologies.
CRISPR/Cas-based epigenome editing technologies hold great promise for identifying novel therapeutic targets, improving gene and cell therapies, and directly addressing the underlying issues in many diseases, all while minimizing risks of genotoxicity often associated with conventional genome editing. Exciting recent advances in CRISPR/Cas-based epigenome editing technologies have drastically enhanced the ability to precisely control the timing, levels, and durations of endogenous gene expression and reprogram epigenetic states in human cells. As a result, epigenome editing is now poised to unlock new biomedical discoveries and treatments for diseases driven by transcriptional and epigenetic dysregulation as well as those stemming from aberrantly repetitive genomic regions or complex genomic arrangements that are difficult to target using conventional genome editing. Additionally, the power of epigenome editors is generating new strategies to control cell fate and function, which has direct and important implications for cell therapies and regenerative medicines. Here, as the first wave of CRISPR/Cas-based epigenome editors move into clinical trials, we cover recent advances as the field looks to address pressing hurdles facing widespread clinical deployment of epigenome editing technologies including delivery, performance, and safety. For instance, the discovery of compact Cas chassis, engineering efforts to reduce effector sizes for efficient delivery, and campaigns to tailor the targeting discrimination of epigenome editors are rapidly progressing, as is research into the development of new effector domains with high specificity, robust performance, and a lack of immunogenicity and cytotoxicity. This exciting progress is quickly moving the community closer to fulfilling the promise of CRISPR/Cas-based epigenome editing as a powerful class of platform technologies for biological discoveries, biotechnological innovations, and medicines.
Research seeking to regulate the function of therapeutic cells can consider options for designing which genes to express, when, at what levels, and for how long. This is a potential application scenario linking the expression-control capabilities of epigenome editing with cell therapy and regenerative medicine research. When comparing tools under development, researchers should examine not only expression-control performance but also delivery feasibility, target discrimination, and immunogenicity and cytotoxicity data. The paper is useful for organizing these research strategies and evaluation criteria. However, the available abstract provides no basis for concluding that the approach can be applied immediately to a specific cell-therapy manufacturing process or reduce production costs.